Pradaxa, also known by its generic name dabigatran etexilate, is a prescription medication used to prevent blood clots in certain patients. It is an oral direct thrombin inhibitor [1].
When can generic dabigatran etexilate be expected?
The patent exclusivity for dabigatran etexilate has expired in many regions, paving the way for generic versions. For instance, the primary U.S. patent for dabigatran etexilate was set to expire in 2023, but patent challenges and settlements can affect the exact timeline for generic availability [2].
What are the approved uses for dabigatran etexilate?
Dabigatran etexilate is prescribed to reduce the risk of stroke and systemic embolism in individuals with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [1].
How does dabigatran etexilate work?
Dabigatran etexilate functions by inhibiting thrombin, a key enzyme in the blood clotting process. By blocking thrombin, it prevents the formation of blood clots [1].
What are the potential risks and side effects of dabigatran etexilate?
A significant risk associated with dabigatran etexilate, like other anticoagulants, is bleeding. Patients taking this medication may experience serious or fatal bleeding events. Other potential side effects include indigestion and nausea [1].
How does dabigatran etexilate compare to other blood thinners?
Dabigatran etexilate belongs to a class of newer oral anticoagulants known as direct oral anticoagulants (DOACs). These medications offer an alternative to older drugs like warfarin. DOACs, including dabigatran, are often favored for their predictable pharmacokinetics, which generally do not require routine monitoring of blood clotting levels [3]. Other DOACs include rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa) [3].
What is the cost difference between brand-name Pradaxa and generic dabigatran etexilate?
Historically, brand-name medications are more expensive than their generic counterparts. Once generic versions of dabigatran etexilate become widely available, they are expected to offer a more affordable treatment option for patients [2].
Who manufactures Pradaxa and its generic versions?
Pradaxa is manufactured by Boehringer Ingelheim. The manufacturers of generic dabigatran etexilate will vary once patents have fully expired and regulatory approval is granted in different markets [4].
Sources:
[1] https://www.drugpatentwatch.com/drugs/dabigatran-etexilate
[2] https://www.drugpatentwatch.com/blog/pradaxa-patent-expiration-and-generic-entry
[3] https://www.drugpatentwatch.com/blog/what-are-the-latest-oral-anticoagulants
[4] https://www.drugpatentwatch.com/companies/boehringer-ingelheim